Close Menu

NEW YORK (360Dx) – Interpace Diagnostics reported after the close of the market on Monday that its first quarter revenues rose 25 percent year over year.

For the three months ended March 31, the firm reported revenues of $6.0 million, up from $4.8 million in the year-ago quarter, but missed the consensus Wall Street estimate of $6.3 million.

Interpace President and CEO Jack Stover said in a statement that the firm had a strong start to the year, driven in part by increasing sales volumes for its gastrointestinal PancraGen business and endocrine ThyGeNext/ThyraMir business.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers have sequenced the genome of the depth-dwelling giant squid.

Prosecutors have charged a former Drexel University professor with theft for allegedly spending federal grant money on adult entertainment and other unrelated expenses, according to the Philadelphia Inquirer.

 

Chris Collins, a former US representative, has been sentenced to more than two years in prison in an insider trading case involving an Australian biotechnology firm, the New York Times reports.

In PNAS this week: Trypanosoma brucei transcripts, estimate of people at risk of inherited retinal disease, and more.